Afssaps releases test results on PIP implants but genotoxicity concerns persist
This article was originally published in RAJ Devices
Executive Summary
Much-awaited tests carried out by French regulatory agency Afssaps on the banned silicone filled breast implants made by Poly Implant Prothèse (PIP) have confirmed the products have an increased risk of rupture1. A number of other healthcare concerns associated with the unapproved and previously untested filler used in the implants have also been verified. The results of ongoing genotoxicity tests, however, are not expected before early next year, the agency said.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.